Flavaglines alleviate doxorubicin cardiotoxicity: Implication of Hsp27

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bernard, Yohann ^a   Ribeiro, Nigel ^a   Thuaud, Frédéric ^a   Türkeri, Gülen ^a   Dirr, Ronan ^a   Boulberdaa, Mounia ^a   Nebigil, Canan G ^a   Désaubry, Laurent ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOXORUBICIN; FL1; FL2; FL3; FL4; FLAVAGLINE DERIVATIVE; HEAT SHOCK PROTEIN 27; LIPOCORTIN 5; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; CARDIOTONIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ASSAY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; IN VITRO STUDY; MALE; MORTALITY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; CELL PROTECTION; CHEMISTRY; CULTURE MEDIUM; FIBROSIS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

MUS;

ANIMALS; APOPTOSIS; BENZOFURANS; CARDIOTONIC AGENTS; CULTURE MEDIA, SERUM-FREE; CYTOPROTECTION; DOXORUBICIN; FIBROSIS; HSP27 HEAT-SHOCK PROTEINS; MALE; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC; PHOSPHORYLATION;

EID: 80055110679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025302     Document Type: Article

References (46)

1. Cortes-Funes H, Coronado C, (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7: 56-60.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
3. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al. (2005) Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23: 2629-2636.
4. Swain SM, Whaley FS, Ewer MS, (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879.
5. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815.
6. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al. (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 15: 1544-1552.
7. Kim S, Salim AA, Swanson SM, Kinghorn AD, (2006) Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem 6: 319-345.
8. Proksch P, Edrada R, Ebel R, Bohnenstengel F, Nugroho B, (2001) Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (Meliaceae). Curr Org Chem 5: 923-938.
9. Fahrig T, Gerlach I, Horvath E, (2005) A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury. Mol Pharmacol 67: 1544-1555.
10. Baines CP, Molkentin JD, (2005) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38: 47-62.
11. Benn SC, Woolf CJ, (2004) Adult neuron survival strategies-slamming on the brakes. Nat Rev Neurosci 5: 686-700.
12. Caporali A, Sala-Newby GB, Meloni M, Graiani G, Pani E, et al. (2008) Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death Differ 15: 299-311.
13. Mattson MP, Kroemer G, (2003) Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 9: 196-205.
14. Thuaud F, Bernard Y, Turkeri G, Dirr R, Aubert G, et al. (2009) Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12. J Med Chem 52: 5176-5187.
15. Yano N, Suzuki D, Endoh M, Tseng A, Stabila JP, et al. (2008) Beta-adrenergic receptor mediated protection against doxorubicin-induced apoptosis in cardiomyocytes: the impact of high ambient glucose. Endocrinology 149: 6449-6461.
16. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, et al. (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: H1466-1483.
17. Voegeli TS, Currie RW, (2009) siRNA knocks down Hsp27 and increases angiotensin II-induced phosphorylated NF-kappaB p65 levels in aortic smooth muscle cells. Inflamm Res 58: 336-343.
18. Esaki M, Takemura G, Kosai K, Takahashi T, Miyata S, et al. (2008) Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 294: H1048-1057.
19. Urayama K, Guilini C, Turkeri G, Takir S, Kurose H, et al. (2008) Prokineticin receptor-1 induces neovascularization and epicardial-derived progenitor cell differentiation. Arterioscler Thromb Vasc Biol 28: 841-849.
20. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L, (2003) Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B receptor signaling. FASEB J 17: 1373-1375.
21. Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB, (2009) Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25: 227-243.
22. Kostenko S, Moens U, (2009) Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 66: 3289-307.
23. Turakhia S, Venkatakrishnan CD, Dunsmore K, Wong H, Kuppusamy P, et al. (2007) Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am J Physiol Heart Circ Physiol 293: H3111-3121.
24. Venkatakrishnan CD, Dunsmore K, Wong H, Roy S, Sen CK, et al. (2008) HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest. Am J Physiol Heart Circ Physiol 294: H1736-1744.
25. Venkatakrishnan CD, Tewari AK, Moldovan L, Cardounel AJ, Zweier JL, et al. (2006) Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am J Physiol Heart Circ Physiol 291: H2680-2691.
26. Shin KD, Lee MY, Shin DS, Lee S, Son KH, et al. (2005) Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 280: 41439-41448.
27. Goubaeva F, Mikami M, Giardina S, Ding B, Abe J, et al. (2007) Cardiac mitochondrial connexin 43 regulates apoptosis. Biochem Biophys Res Commun 352: 97-103.
28. Berdichevski A, Meiry G, Milman F, Reiter I, Sedan O, et al. (2010) TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. J Pharmacol Exp Ther 332: 413-20.
29. van Dalen EC, Caron HN, Dickinson HO, Kremer LC, (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev pp. CD003917.
30. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, et al. (2007) Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer 96: 226-230.
31. Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, et al. (2005) Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 7: 67-76.
32. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE, (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578.
33. Kim R, (2005) Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103: 1551-1560.
34. Liu L, Zhang X, Qian B, Min X, Gao X, et al. (2007) Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 9: 762-769.
35. Li K, Sung RY, Huang WZ, Yang M, Pong NH, et al. (2006) Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113: 2211-2220.
36. Li L, Takemura G, Li Y, Miyata S, Esaki M, et al. (2006) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113: 535-543.
37. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, et al. (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119: 99-106.
38. Imondi AR, (1998) Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. Semin Oncol 25: 22-30.
39. Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, et al. (2000) Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circ Res 86: 8-14.
40. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, et al. (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41: 845-854.
41. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, et al. (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30: 243-54.
42. Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, et al. (2005) Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol 5: 269-283.
43. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, et al. (2008) Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118: 2651-2660.
44. Griffin MO, Fricovsky E, Ceballos G, Villarreal F, Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 299: C539-548.
45. Lai HC, Yeh YC, Ting CT, Lee WL, Lee HW, et al. Doxycycline suppresses doxorubicin-induced oxidative stress and cellular apoptosis in mouse hearts. Eur J Pharmacol 644: 176-187.
46. Mai A, Rotili D, Valente S, Kazantsev AG, (2009) Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 15: 3940-3957.